Instructions For the fiscal year ended June 30, 2022, calculate the following for Amerigo Laboratories, Inc. a. Basic earnings per share. b. Diluted earnings per share.

Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter5: The Income Statement And The Statement Of Cash Flows
Section: Chapter Questions
Problem 11P: Net Income and Comprehensive Income At the beginning of 2019, JR Companys shareholders equity was as...
icon
Related questions
Question
Jean Mier Serawak, comptroller at Amerigo Laboratories, Inc., a public company, is currently
preparing the calculation for basic and diluted earnings per share and the related disclosure for
Amerigo's financial statements. Selected financial information for the fiscal year ended June 30,
2022, is shown below.
Amerigo Laboratories, Inc.
Selected Statement of Financial Position Information
June 30, 2022
Equity
Share capital-preference, 6% cumulative, P50 par value, 100,000
shares authorized, 25,000 shares issued and outstanding
Share capital-ordinary, P1 par, 10,000,000 shares authorized,
1,000,000 shares issued and outstanding
Share premium-ordinary (includes any amounts for options and
conversions)
Retained earnings
Total equity
P 1,250,000
1,000,000
4,000,000
6,000,000
P12,250,000
Long-term debt
Notes payable, 10%
Convertible bonds payable
10% bonds payable
Total long-term debt
P 1,000,000
5,000,000
6,000,000
P12,000,000
The following transactions have also occurred at Amerigo.
1. Options were granted on July 1, 2021, to purchase 200,000 shares at P15 per share. Although
no options were exercised during fiscal year 2022, the average price per ordinary share during
fiscal year 2022 was P20 per share.
2. Each bond was issued at face value. The convertible bonds will convert into ordinary shares at
50 shares per P1,000 bond. The conversion is exercisable after 5 years, and the bonds were
issued in 2020. The interest on the liability component of the convertible bonds payable for the
fiscal year ending June 30, 2022, was P450,000.
3. The preference shares were issued in 2020.
4. There are no preference dividends in arrears; however, preference dividends were not
declared in fiscal year 2022.
5. The 1,000,000 ordinary shares were outstanding for the entire 2022 fiscal year.
6. Net income for fiscal year 2022 was P1,500,000, and the average income tax rate is
40%.
Instructions
For the fiscal year ended June 30, 2022, calculate the following for Amerigo
Laboratories, Inc.
a. Basic earnings per share.
b. Diluted earnings per share.
Transcribed Image Text:Jean Mier Serawak, comptroller at Amerigo Laboratories, Inc., a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Amerigo's financial statements. Selected financial information for the fiscal year ended June 30, 2022, is shown below. Amerigo Laboratories, Inc. Selected Statement of Financial Position Information June 30, 2022 Equity Share capital-preference, 6% cumulative, P50 par value, 100,000 shares authorized, 25,000 shares issued and outstanding Share capital-ordinary, P1 par, 10,000,000 shares authorized, 1,000,000 shares issued and outstanding Share premium-ordinary (includes any amounts for options and conversions) Retained earnings Total equity P 1,250,000 1,000,000 4,000,000 6,000,000 P12,250,000 Long-term debt Notes payable, 10% Convertible bonds payable 10% bonds payable Total long-term debt P 1,000,000 5,000,000 6,000,000 P12,000,000 The following transactions have also occurred at Amerigo. 1. Options were granted on July 1, 2021, to purchase 200,000 shares at P15 per share. Although no options were exercised during fiscal year 2022, the average price per ordinary share during fiscal year 2022 was P20 per share. 2. Each bond was issued at face value. The convertible bonds will convert into ordinary shares at 50 shares per P1,000 bond. The conversion is exercisable after 5 years, and the bonds were issued in 2020. The interest on the liability component of the convertible bonds payable for the fiscal year ending June 30, 2022, was P450,000. 3. The preference shares were issued in 2020. 4. There are no preference dividends in arrears; however, preference dividends were not declared in fiscal year 2022. 5. The 1,000,000 ordinary shares were outstanding for the entire 2022 fiscal year. 6. Net income for fiscal year 2022 was P1,500,000, and the average income tax rate is 40%. Instructions For the fiscal year ended June 30, 2022, calculate the following for Amerigo Laboratories, Inc. a. Basic earnings per share. b. Diluted earnings per share.
Expert Solution
steps

Step by step

Solved in 2 steps

Blurred answer
Knowledge Booster
Ratio Analysis
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning
Income Tax Fundamentals 2020
Income Tax Fundamentals 2020
Accounting
ISBN:
9780357391129
Author:
WHITTENBURG
Publisher:
Cengage
Cornerstones of Financial Accounting
Cornerstones of Financial Accounting
Accounting
ISBN:
9781337690881
Author:
Jay Rich, Jeff Jones
Publisher:
Cengage Learning
Managerial Accounting: The Cornerstone of Busines…
Managerial Accounting: The Cornerstone of Busines…
Accounting
ISBN:
9781337115773
Author:
Maryanne M. Mowen, Don R. Hansen, Dan L. Heitger
Publisher:
Cengage Learning
Century 21 Accounting Multicolumn Journal
Century 21 Accounting Multicolumn Journal
Accounting
ISBN:
9781337679503
Author:
Gilbertson
Publisher:
Cengage
Century 21 Accounting General Journal
Century 21 Accounting General Journal
Accounting
ISBN:
9781337680059
Author:
Gilbertson
Publisher:
Cengage